Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ParkerVision, Inc.'s SEC filings document an OTCQB-traded Florida corporation focused on proprietary RF technologies, wireless applications, licensing, and patent enforcement. Its 8-K filings report operating results, legal and appellate developments involving patent claims, and material events that affect the company's capital structure and disclosure record.
The filing record also covers registered direct common stock offerings under a Form S-3 shelf registration statement, exchanges of convertible promissory notes for common stock, unregistered equity issuance disclosures, and executive compensation arrangements under the company's long-term incentive plan. These documents address governance approvals, share-based awards, financing terms, and risk references tied to patent proceedings and funding activity.
ParkerVision, Inc. registers 13,342,953 shares of Common Stock for resale under a prospectus supplement dated March 13, 2026. The resale registration covers shares held by selling stockholders and the company states it will not receive proceeds from those resales.
The supplement also attaches a Form 8-K reporting that the company issued an aggregate of 3,277,099 shares on March 13, 2026 in exchange for cancellation of convertible notes with aggregate principal of $675,000 and accrued interest of approximately $13,200 at an exchange price of $0.21 per share, using the Section 3(a)(9) exemption. The prospectus notes the company would receive up to $2,833,756 if certain warrants are exercised for cash.
ParkerVision, Inc. files a prospectus supplement registering 5,871,584 shares of Common Stock for resale by selling stockholders under its Prospectus dated September 2, 2020.
The supplement incorporates a Current Report on Form 8-K dated March 13, 2026, which reports that the company issued an aggregate of 3,277,099 shares of Common Stock on March 13, 2026 in exchange for cancellation of convertible promissory notes with an aggregate outstanding principal amount of $675,000 and accrued interest of approximately $13,200. The company states it will not receive proceeds from the resale of the registered shares.
ParkerVision, Inc. supplements its existing prospectus to register the resale of 16,809,295 shares of Common Stock by selling stockholders. The prospectus supplement explains that the registered shares consist of convertible-note conversions, private placements, shares issued for services and payables, and up to 5,000,000 and 200,000 shares issuable upon exercise of warrants held by Aspire Capital and Tailwinds, respectively.
The company states it will not receive proceeds from the resale by selling stockholders; however, if the Aspire and Tailwinds warrants are exercised for cash, the company would receive up to an aggregate of $3,900,000, which it expects to use for general working capital and corporate purposes. The supplement incorporates a Form 8-K dated March 13, 2026 describing exchange agreements that resulted in issuance of 3,277,099 shares to cancel convertible notes with aggregate principal of $675,000.
ParkerVision, Inc. files a prospectus supplement registering 18,014,164 shares of Common Stock for resale by selling stockholders under its existing prospectus.
The supplement states the registered shares consist of convertible-note conversions, consulting-share issuances and a warrant, and that the company will not receive proceeds from resales by the selling stockholders. The supplement also attaches an 8-K dated March 13, 2026 reporting that the company issued 3,277,099 shares pursuant to exchanges that cancelled convertible notes with aggregate principal of $675,000 plus approximately $13,200 of accrued interest, issued at an exchange price of $0.21 per share.
ParkerVision, Inc. files a prospectus supplement to register 17,189,660 shares of Common Stock for resale by selling stockholders under prior registration statements. The supplement incorporates the Company’s Form 8-K dated March 13, 2026 concerning exchange transactions.
Separately, the Company issued 3,277,099 shares of Common Stock on March 13, 2026, in exchange under Section 3(a)(9) for cancellation of convertible notes with an aggregate principal of $675,000 plus approximately $13,200 of accrued interest at an exchange price of $0.21 per share.
ParkerVision, Inc. registered 12,800,000 shares of Common Stock by prospectus supplement dated March 13, 2026.
The supplement states the 12,800,000 shares consist of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from selling stockholders; if the warrant is exercised for cash, the company would receive up to $800,000 to fund patent enforcement and working capital.
Separately, the company entered into exchange agreements dated March 13, 2026 to cancel convertible notes: the company issued 3,277,099 shares at an exchange price of $0.21 per share in exchange for cancellation of notes with aggregate principal of $675,000 plus approximately $13,200 of accrued interest.
ParkerVision, Inc. entered into exchange agreements with certain holders of its convertible promissory notes. The holders agreed to swap the notes’ outstanding principal and accrued interest for common stock at an exchange price of $0.21 per share under a Section 3(a)(9) registration exemption.
The company issued 3,277,099 shares of common stock to these holders in exchange for the cancellation of notes with an aggregate outstanding principal amount of $675,000 and accrued and unpaid interest of approximately $13,200. The exchanged notes were cancelled and are no longer outstanding, reducing this portion of ParkerVision’s debt.
ParkerVision reported an insider equity award to its leader. On January 22, 2026, Chief Executive Officer and director Jeffrey Parker received a grant of a performance-based nonqualified stock option covering 8,000,000 shares of ParkerVision common stock with an exercise price of $0.24 per share. The option vests based on specified performance conditions that are measured quarterly over a five-year performance period. Any portion of the option that has not vested by January 22, 2031 will be cancelled. After this grant, Parker is shown as directly holding 8,000,000 derivative securities related to this option.
ParkerVision Inc. Chief Financial Officer Cynthia L. French reported the grant of two nonqualified stock option awards. On January 22, 2026, she was awarded 500,000 nonqualified stock options with an exercise price of $0.24 per share, exercisable in four equal bi-annual installments beginning July 22, 2026. She also received 500,000 performance-based nonqualified stock options at an exercise price of $0.24 per share, which vest based on specified performance conditions measured quarterly over a five-year period. Any portion of this performance-based grant that does not vest by January 22, 2031 will be cancelled.
ParkerVision Inc. director Paul A. Rosenbaum received a stock option grant as part of his 2026 Board compensation. On January 22, 2026, he was awarded an option to purchase 370,000 shares of ParkerVision common stock at $0.24 per share, held directly. This option represents his beneficial ownership of 370,000 derivative securities after the transaction.
The option vests in two equal installments, with half vesting on July 22, 2026 and the remaining half on January 22, 2027, aligning the award with continued Board service over that period.